Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18083019 | 0.75 | MAPT (0.61) | BCHEACHEKDM4EMAPTHTT | |
| SCHEMBL13564043 | 0.75 | MAPT (0.61) | BCHEACHEKDM4EMAPTHTT | |
| SCHEMBL793546 | 0.71 | BCHE (0.56) | BCHEACHEKDM4EMAPTHTT | |
| SCHEMBL15236170 | 0.71 | HASPIN (0.74) | HASPINDYRK1A | |
| SCHEMBL23877038 | 0.69 | CYP2A6 (0.41) | ACHEKDM4ERAB9ATDP1ALDH1A1 | |
| SCHEMBL24667912 | 0.69 | BCHE (0.45) | BCHEACHEKDM4EMAPTHTT | |
| SCHEMBL20313213 | 0.68 | ALKBH5 (0.68) | BCHEACHEKDM4EMAPTHTT | |
| SCHEMBL18083034 | 0.68 | ALKBH5 (0.58) | BCHEACHEKDM4EMAPTHTT | |
| SCHEMBL12123801 | 0.68 | MAPK8 (0.38) | BCHEACHEKDM4EMAPTHSD17B10 | |
| SCHEMBL28658652 | 0.68 | BCHE (0.51) | BCHEACHEHASPINMAOADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9107914-B2 | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| EP-2519238-B1 | BETA-CARBOLINES FOR THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2014-08-13 | — | — | EP | claimed |
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| US-9107914-B2 | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9107914-B2 | Beta-carbolines for use in the treatment of hearing loss and vertigo | AUDIOCURE PHARMA GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2519238-B1 | BETA-CARBOLINES FOR THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | AUDIOCURE PHARMA GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011079841-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | ROMMELSPACHER HANS (DE) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028958-A1 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO | CBFB, ADRA2B, SLC6A12 | BCHE 92/4885ACHE 576/4885KDM4E 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.